7e159b1cfa
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-04-18-trump-executive-order-psychedelics-mental-health.md - Domain: health - Claims: 1, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
18 lines
No EOL
1,021 B
Markdown
18 lines
No EOL
1,021 B
Markdown
# Transcend Therapeutics
|
|
|
|
**Type:** Biotech company
|
|
**Focus:** MDMA-like compounds for PTSD
|
|
**Lead Asset:** TSND-201 (methylone)
|
|
**Status:** Breakthrough Therapy Designation; National Priority Voucher recipient
|
|
|
|
## Overview
|
|
|
|
Transcend Therapeutics is developing methylone (TSND-201), an MDMA-like compound for PTSD treatment. The company received FDA Breakthrough Therapy Designation and was awarded a National Priority Voucher on April 24, 2026 under the Trump Executive Order on psychedelics.
|
|
|
|
## Strategic Context
|
|
|
|
Methylone represents a distinct chemical entity from MDMA, potentially addressing the regulatory challenges that led to MDMA-AT's FDA rejection. By pursuing a related molecule with cleaner trial design, Transcend is attempting to capture MDMA's therapeutic mechanism while avoiding its regulatory history.
|
|
|
|
## Timeline
|
|
|
|
- **2026-04-24** — Received FDA National Priority Voucher for TSND-201 methylone (PTSD) under Trump Executive Order, compressing review timeline to 1-2 months post-application |